Roivant Sciences Ltd reports results for the quarter ended December 31 - Earnings Summary

Roivant Sciences

10/02/2025 14:31

* Roivant Sciences Ltd  ROIV.OQ  reported quarterly adjusted
earnings of 23 cents​​ per share for the quarter ended December
31, higher than the same quarter last year, when the company
reported EPS of -30 cents.  The mean expectation of
nine analysts for the quarter was for a loss of 28 cents per
share. Wall Street expected results to range from -34 cents
to -16 cents per share.
    * Revenue fell 75.7% to $9.02 million from a year ago;
analysts
expected $15.99 million. 
    * Roivant Sciences Ltd's reported EPS for the quarter was 23
cents​.
    * The company reported quarterly net income of $169.38
million.
    * Roivant Sciences Ltd shares had fallen by 7.9% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Roivant Sciences
Ltd is $17.00 
This summary was machine generated from LSEG data February 10 at
02:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -0.28          0.23           Beat
 Sep. 30 2024      -0.26          -0.31          Missed
 Jun. 30 2024      -0.26          0.12           Beat
 Mar. 31 2024      -0.30          -0.19          Beat